Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
1.75
+0.02 (1.16%)
Apr 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.71 - 1.77
52 week 1.11 - 3.31
Open 1.75
Vol / Avg. 529,564.00/866,433.00
Mkt cap 261.98M
P/E     -
Div/yield     -
EPS -0.35
Shares 149.70M
Beta 0.80
Inst. own 28%
Jun 23, 2014
Navidea Biopharmaceuticals Inc Annual Shareholder Meeting (Estimated) Add to calendar
May 5, 2014
Q1 2014 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 6, 2014
Q4 2013 Navidea Biopharmaceuticals Inc Earnings Release
Mar 6, 2014
Q4 2013 Navidea Biopharmaceuticals Inc Earnings Conference Call - Webcast
Feb 10, 2014
Navidea Biopharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -2570.54% -3776.61%
Operating margin -2439.90% -3521.10%
EBITD margin - -3363.98%
Return on average assets -122.23% -163.32%
Return on average equity -2273.12% -
Employees 47 -
CDP Score - -

Address

Suite 300, 425 Metro Place North
DUBLIN, OH 43017-1367
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�s disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Officers and directors

Gordon A. Troup Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Thomas H. Tulip Ph.D. President, Chief Business Officer
Age: 60
Bio & Compensation  - Reuters
Mark J. Pykett Ph.D. Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Brent L. Larson Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. SVP - Pharmaceutical Research and Clinical Development
Age: 66
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Strategy
Age: 61
Bio & Compensation  - Reuters
Cornelia B. Reininger M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Director
Age: 54
Bio & Compensation  - Reuters
Perry A. Karsen Director
Age: 58
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 56
Bio & Compensation  - Reuters